Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

This study is testing a personalized cancer vaccine approach for patients with bladder cancer or other solid tumors who have had surgery but show signs of residual microscopic disease (cancer that may still be present at a molecular level even though scans look clear). The vaccine is custom-made based on the patient's specific tumor mutations. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with muscle-invasive bladder cancer or upper urinary tract cancer - You have had complete surgical removal of the tumor - There is evidence of residual molecular disease after surgery - Your overall health is acceptable (ECOG ≤ 2) **You may NOT be eligible if...** - Your cancer has visibly spread (metastatic disease on scans) - You have not had complete surgical removal - You have serious immune system disorders - You have received certain prior treatments that would disqualify you Talk to your doctor to see if this trial is right for you.